Lisa Krassnig

Lisa Krassnig

Auto-generated profile, based on publicly available information

Lisa Krassnig

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YCYehuda Z. Cohen
Yehuda Z. Cohen
JLJulio C.C. Lorenzi
Julio C.C. Lorenzi
LKLisa Krassnig
Lisa Krassnig
JBJohn Barton
John Barton
LBLeah Burke
Leah Burke
MNMichel C. Nussenzweig
Michel C. Nussenzweig
A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir was evaluated by quantitative and qualitative viral outgrowth assay (Q2VOA) at entry and after 6 mo. There were no significant quantitative changes in the size of the reservoir before ATI, and the composition of circulating reservoir clones varied in a manner that did not correlate with 3BNC117 sensitivity. 3BNC117 binding site amino acid variants found in rebound viruses preexisted in the latent reservoir. However, only 3 of 217 rebound viruses were identical to 868 latent viruses isolated by Q2VOA and near full-length sequencing. Instead, 63% of the rebound viruses appeared to be recombinants, even in individuals with 3BNC117-resistant reservoir viruses. In conclusion, viruses emerging during ATI in individuals treated with 3BNC117 are not the dominant species found in the circulating latent reservoir, but frequently appear to represent recombinants of latent viruses. Graphical Abstract